🇺🇸 epoetin beta [NeoRecormon] in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 19

Most-reported reactions

1. Nephrogenic Systemic Fibrosis — 6 reports (31.58%)
2. Erythema — 2 reports (10.53%)
3. Haemodialysis — 2 reports (10.53%)
4. Oedema Peripheral — 2 reports (10.53%)
5. Pain In Extremity — 2 reports (10.53%)
6. Aortic Arteriosclerosis — 1 report (5.26%)
7. Arthralgia — 1 report (5.26%)
8. Asthenia — 1 report (5.26%)
9. Cardiomegaly — 1 report (5.26%)
10. Colon Cancer — 1 report (5.26%)

Source database →

Frequently asked questions

Is epoetin beta [NeoRecormon] approved in United States?

epoetin beta [NeoRecormon] does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for epoetin beta [NeoRecormon] in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.